Date: 2016-10-10
Type of information: Collaboration agreement
Compound: Humabody® -based therapeutics
Company: Millenium Pharmaceuticals (USA - MA), wholly owned subsidiary of Takeda Pharmaceutical (Japan) Crescendo Biologics (UK)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: monoclonal antibody/antibody drug conjugate. Humabody® therapeutics are based on Crescendo Biologics' proprietary fully human VH domain technology platform. Crescendo is building a pipeline of new differentiated medicines, including Humabody® Drug Conjugates (HDCs) and multi-specific immuno-oncology (IO) modulators, through in-house development and strategic partnerships.
Disease:
Details: * On October 10, 2016, Crescendo Biologics and Takeda Pharmaceutical announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialization of Humabody® -based therapeutics for cancer indications with a high unmet medical need. Crescendo will use its proprietary transgenic platform and engineering expertise to discover and optimally configure Humabody® candidates (Humabody® Drug Conjugates and Immuno-Oncology modulators) against multiple targets selected by Takeda. Takeda signed agreements with Crescendo Biologics through its wholly-owned subsidiary, Millennium Pharmaceuticals.
Financial terms: Under the terms of the agreement, Crescendo is eligible to receive up to $36 million, in a combination of an upfront payment, investment, research funding and preclinical milestones. Takeda will have the right to develop and commercialize Humabody®-based therapeutics resulting from the collaboration. Crescendo is also eligible to receive further clinical development, regulatory and sales-based milestone payments of up to $754 million. In addition, Crescendo will be eligible to receive royalties on Humabody®-based product sales by Takeda.
Latest news:
